<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727491</url>
  </required_header>
  <id_info>
    <org_study_id>ANAE-182-10</org_study_id>
    <nct_id>NCT02727491</nct_id>
  </id_info>
  <brief_title>Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children?</brief_title>
  <official_title>A Prospective Randomized Double-blind Placebo Controlled Trial; Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With Institutional ethics board and Health Canada approval, pediatric patients (ages 3-12)
      undergoing tonsillectomy or adenotonsillectomy (under standardized anesthesia) will be
      randomized to receive dextromethorphan hydrobromide (1mg/kg orally) 30 min preoperatively and
      again 8 hours postoperatively OR placebo (syrup identical in taste, appearance and volume) at
      the same time points. The primary outcome is an integrated assessment of perioperative pain
      scores and opioid use for 24 hours postoperatively. Secondary outcomes include nausea,
      vomiting, respiratory depression, and bleeding for 24 hours postoperatively. Our hypothesis
      is that dextromethorphan will decrease the incidence/severity of post-tonsillectomy pain. The
      improved pain control will be apparent through reduced opioid consumption and integrated pain
      scores. This will result in a reduced incidence of opioid-related side effects and adverse
      events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With Institutional ethics board and Health Canada approval and parental consent and child
      assent, pediatric patients (ages 3-12) undergoing tonsillectomy or adenotonsillectomy (under
      standardized anesthesia) will be randomized to receive dextromethorphan hydrobromide (1mg/kg
      orally) 30 min preoperatively and again 8 hours postoperatively OR placebo (syrup identical
      in taste, appearance and volume) at the same time points. The primary outcome is an
      integrated assessment of perioperative pain scores and opioid use for 24 hours
      postoperatively. Pain scores were collected preoperatively at rest and then at 1,2,3,8,9,10
      and 24 hours postoperatively using the validated Children's Hospital of Eastern Ontario Pain
      Scale (CHEOPS). Secondary outcomes include nausea, vomiting, respiratory depression, and
      bleeding recorded by blinded observers for 24 hours postoperatively.

      Our hypothesis is that dextromethorphan will decrease the incidence/severity of
      post-tonsillectomy pain. The improved pain control will be apparent through reduced opioid
      consumption and integrated pain scores. This will result in a reduced incidence of
      opioid-related side effects and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>integrated assessment of pain scores and opioid use</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>The Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) will be measured at rest 24 hours postoperatively and this will be integrated with total opioid consumption at 24 hours postoperatively. This will be achieved by converting both pain scores and opioid consumption to % change. The % differences for each of the 2 variables are then added together on a per-subject basis to provide a summated % difference. The individual and summated % differences can then be plotted on a single graph and the integrated ranks of the experimental and control groups can be compared with standard statistical tests.(1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>opioid-related adverse effects</measure>
    <time_frame>up to 24 hours postoperatively</time_frame>
    <description>nausea, vomiting, respiratory depression, bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>1,2,3,8,9 and 10 hours postoperatively</time_frame>
    <description>Pain scores at rest on the CHEOPS pain scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>dextromethorphan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).</description>
    <arm_group_label>dextromethorphan</arm_group_label>
    <other_name>dextromethorphan hydrobromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist's (ASA) physical classification I and II

          -  tonsillectomy or adenotonsillectomy

          -  admission to extended postoperative care unit

        Exclusion Criteria:

          -  use of monoamine oxidase inhibitors, serotonin reuptake inhibitors or tricyclic
             antidepressants

          -  requirement of preoperative sedation

          -  recent dextromethorphan use (&lt;24 h before surgery)

          -  intolerance, sensitivity or contraindication to any agents used in the study

          -  pre-existing chronic pain or chronic analgesic use

          -  body mass index (BMI) for age percentile greater than 90

          -  confounding procedural factors which might affect the validity of the data

          -  inability to adhere to study protocol

          -  contraindication to volatile anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Rooney, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <reference>
    <citation>Silverman DG, O'Connor TZ, Brull SJ. Integrated assessment of pain scores and rescue morphine use during studies of analgesic efficacy. Anesth Analg. 1993 Jul;77(1):168-70.</citation>
    <PMID>8317727</PMID>
  </reference>
  <reference>
    <citation>Kawamata T, Omote K, Kawamata M, Namiki A. Premedication with oral dextromethorphan reduces postoperative pain after tonsillectomy. Anesth Analg. 1998 Mar;86(3):594-7.</citation>
    <PMID>9495423</PMID>
  </reference>
  <reference>
    <citation>Dawson GS, Seidman P, Ramadan HH. Improved postoperative pain control in pediatric adenotonsillectomy with dextromethorphan. Laryngoscope. 2001 Jul;111(7):1223-6.</citation>
    <PMID>11568544</PMID>
  </reference>
  <reference>
    <citation>Kelly LE, Sommer DD, Ramakrishna J, Hoffbauer S, Arbab-Tafti S, Reid D, Maclean J, Koren G. Morphine or Ibuprofen for post-tonsillectomy analgesia: a randomized trial. Pediatrics. 2015 Feb;135(2):307-13. doi: 10.1542/peds.2014-1906.</citation>
    <PMID>25624387</PMID>
  </reference>
  <reference>
    <citation>Hasan RA, Kartush JM, Thomas JD, Sigler DL. Oral dextromethorphan reduces perioperative analgesic administration in children undergoing tympanomastoid surgery. Otolaryngol Head Neck Surg. 2004 Nov;131(5):711-6.</citation>
    <PMID>15523452</PMID>
  </reference>
  <reference>
    <citation>Rose JB, Cuy R, Cohen DE, Schreiner MS. Preoperative oral dextromethorphan does not reduce pain or analgesic consumption in children after adenotonsillectomy. Anesth Analg. 1999 Apr;88(4):749-53.</citation>
    <PMID>10195517</PMID>
  </reference>
  <reference>
    <citation>Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth. 2000 Jun;47(6):585-96. Review.</citation>
    <PMID>10875724</PMID>
  </reference>
  <reference>
    <citation>Brown KA, Laferri√®re A, Lakheeram I, Moss IR. Recurrent hypoxemia in children is associated with increased analgesic sensitivity to opiates. Anesthesiology. 2006 Oct;105(4):665-9.</citation>
    <PMID>17006062</PMID>
  </reference>
  <reference>
    <citation>Steinberg GK, Bell TE, Yenari MA. Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg. 1996 May;84(5):860-6.</citation>
    <PMID>8622162</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Rachel Rooney</investigator_full_name>
    <investigator_title>Dr. Rachel Rooney</investigator_title>
  </responsible_party>
  <keyword>opioid analgesics,</keyword>
  <keyword>opioid consumption</keyword>
  <keyword>adverse effects</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>tonsillectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

